Evidence map›Paper›PMID 29619682›Full record

Trial reportEuropean journal of drug metabolism and pharmacokinetics2018

A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.

Marc Cantillon, Robert Ings, Arul Prakash, Laxminarayan Bhat

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of drug metabolism and pharmacokinetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Marc CantillonReviva Pharmaceuticals, Inc., 1250 Oakmead Parkway, Suite 210, Sunnyvale, CA, 94085, USA.
Robert IngsReviva Pharmaceuticals, Inc., 1250 Oakmead Parkway, Suite 210, Sunnyvale, CA, 94085, USA.
Arul PrakashReviva Pharmaceuticals, Inc., 1250 Oakmead Parkway, Suite 210, Sunnyvale, CA, 94085, USA.
Laxminarayan BhatReviva Pharmaceuticals, Inc., 1250 Oakmead Parkway, Suite 210, Sunnyvale, CA, 94085, USA. lbhat@revivapharma.com.ORCID http://orcid.org/0000-0003-0503-8537

Funding

Reviva Pharmaceuticals, Inc Not applicable
6 · The paper itself

Abstract

BACKGROUND AND

objectiveRP5063 is a novel multimodal dopamine (D)-serotonin (5-HT) stabilizer possessing partial agonist activity for D

methodsPharmacokinetic sample data (175 patients on RP5063; 28 doses/patient) were analyzed, utilized one- and two-compartment models, and evaluated the impact of covariates. Pharmacodynamic analysis involved development of an E

resultsThe pharmacokinetic analysis identified a one-compartment model incorporating body mass index influence on volume as the optimum construct, with fixed-effect parameters: (1) oral clearance (Cl/F), 5.11 ± 0.11 L/h; (2) volume of distribution (V

conclusionsPharmacokinetics of RP5063 behaved predictably and consistently. Pharmacodynamics were characterized using an E

Indexed as

Models, BiologicalAdministration, OralAdolescentAdultAgedAntipsychotic AgentsDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMiddle AgedOrganic ChemicalsPsychotic DisordersSchizophreniaYoung AdultAntipsychotic AgentsOrganic ChemicalsRP5063

Identifiers

PMID29619682
PMCPMC6133081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.